Chris Compton

TL;DR: U-BIOPRED is characterised by poor symptom control, increased comorbidity and airway inflammation, despite high levels of treatment, and is well suited to identify asthma phenotypes using the array of "omic" datasets that are at the core of this systems medicine approach.

TL;DR: The U-BIOPRED international consensus on the definition and diagnosis of severe asthma is presented, aligning the latest concepts in adults as well as in children and provides a systematic algorithmic approach to the evaluation of patients presenting with chronic severe asthma symptoms for use in clinical research and specialised care.

TL;DR: Clustering based on clinicophysiologic parameters yielded 4 stable and reproducible clusters of asthmatic patients that associate with different pathobiological pathways.

TL;DR: Cilomilast 15 mg twice daily significantly improved FEV(1) compared with placebo and FVC and peak expiratory flow were improved, suggesting that this orally active, potent, selective phosphodiesterase type 4 inhibitor might be an effective maintenance treatment for COPD.

TL;DR: Bronchial biopsies demonstrated that cilomilast treatment was associated with reductions in CD8+ and CD68+ cells, the first demonstration of reduction by any agent of airway tissue inflammatory cells characteristic of COPD.